Is Solana Company (NASDAQ:HSDT) a buy in 2026?
Hold. Solana Company is a wait-and-watch at today's price, not a fresh buy.
A SOL treasury wrapper trading below book, bolted onto a leftover neuro-device business. Interesting vehicle, awkward structure, binary outcome.
Where HSDT is headed
Solana Company is what happens when a small-cap medical device shell (formerly Helius Medical) gets repurposed as a public-market proxy for holding SOL. The thesis the company is selling is simple: accumulate SOL on balance sheet, grow SOL-per-share over time, and let the market pay a premium to NAV the way it has for the Bitcoin treasury cohort. At $146M market cap and a 0.80 price-to-book, the market is doing the opposite today. It's pricing the vehicle at a discount to the tokens it holds, which tells you something about how investors feel about Solana treasuries that are not named DeFi Development Corp or Sol Strategies.
Read the full Compass Direction on HSDT
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $2.24).
See the full HSDT analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Solana Company (NASDAQ:HSDT) a buy in 2026?
Hold. Solana Company is a wait-and-watch at today's price, not a fresh buy. A SOL treasury wrapper trading below book, bolted onto a leftover neuro-device business. Interesting vehicle, awkward structure, binary outcome.
What is HSDT's Compass Score?
Solana Company scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for HSDT?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the HSDT page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.